Clinical Trials Logo

Cross Infection clinical trials

View clinical trials related to Cross Infection.

Filter by:

NCT ID: NCT00156377 Completed - Clinical trials for Staphylococcal Infections

Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections

Start date: November 2002
Phase: Phase 4
Study type: Interventional

In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections.

NCT ID: NCT00151606 Completed - Clinical trials for Nosocomial Infections

Comparison of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus.

Start date: December 2002
Phase: N/A
Study type: Interventional

Nosocomial infections is a major problem in intensive care units due to both growing incidence and pathogens implicated which become increasingly resistant to antibiotics. According to the Center for Disease Control (USA), Staphylococcus aureus is responsible for approximately 10% of cases. In Europe, 79% of the S.aureus strains are resistant to methicillin, a routinely used antibiotic. Recommendations for the prevention of transmission of these resistant bacteria are rarely based on controlled trials. Therefore the aim of our study is to evaluate two protocols to prevent the acquisition of methicillin-resistant S. Aureus in intensive care units: either a reinforced isolation precautions protocol or a standard precautions protocol.

NCT ID: NCT00150332 Completed - Clinical trials for Infections, Nosocomial

Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Start date: January 2003
Phase: Phase 3
Study type: Interventional

Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan

NCT ID: NCT00130221 Completed - Sepsis Clinical Trials

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

Start date: June 2005
Phase: Phase 1
Study type: Interventional

Patients in the intensive care unit are at risk for many infections because the severity of illness and the procedures necessary to care for them. This study is designed to look at a change in bathing procedure as a method to reduce infections. Currently, patients at John H. Stroger Hospital are cleansed with soap and water. However, preliminary data from a previous study at Rush University Medical Center showed that a chlorhexidine (CHG)-impregnated cloth (2% CHG Antiseptic Cloth system, Sage Products, Inc.) decreased skin bacteria and may lessen bacteria in the blood stream. The 2% CHG Antiseptic Cloth system is a non-irritating, no-rinse, cleansing and moisturizing product that contains 2% chlorhexidine gluconate. The goal of this proposed study is to further evaluate the effectiveness of the 2% CHG Antiseptic Cloth system compared with soap and water in cleansing the skin and preventing bacteria from entering the bloodstream.

NCT ID: NCT00122057 Completed - Clinical trials for Respiratory Tract Diseases

Impact of Antibiotic Treatment on Outcome in Patients With Ventilator-Associated Tracheobronchitis

Start date: June 2005
Phase: N/A
Study type: Interventional

The aim of this study is to determine whether antibiotic treatment could reduce mechanical ventilation duration in patients with nosocomial tracheobronchitis acquired under mechanical ventilation.

NCT ID: NCT00113191 Completed - Sepsis Clinical Trials

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

Start date: May 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to show whether Veronate, a donor-selected staphylococcal human immune globulin intravenous (IGIV), can prevent an infection in the blood caused by staphylococcal bacteria in premature babies weighing between 500 and 1250 grams at birth. Babies are enrolled between Day of Life 3 and 5. Babies are randomized to either Veronate or placebo (50-50 chance of either). Babies can receive up to 4 doses of the study drug on Study Days 1, 3, 8 and 15 and are followed until Study Day 70 or discharge from the hospital.

NCT ID: NCT00105625 Completed - Malnutrition Clinical Trials

VA Nutrition Study on Immune Function

Start date: March 2003
Phase: N/A
Study type: Observational

Hospital-acquired infections can occur five times as frequently in rehabilitation patients than in other hospital admissions. We postulate that this high infection rate may be due to nutritional problems frequently experienced in these patients. In this study, we examine the role of nutrition in inpatient geriatric rehabilitation patients' immune function and infection rates.

NCT ID: NCT00081744 Completed - Clinical trials for Gram-Positive Bacterial Infections

Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

Start date: November 2002
Phase: Phase 3
Study type: Interventional

Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.

NCT ID: NCT00081575 Completed - Bacterial Pneumonia Clinical Trials

Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia

Start date: January 2004
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.

NCT ID: NCT00079885 Completed - Clinical trials for Community Acquired Pneumonia

Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia

Start date: November 2003
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment of subjects with CAP requiring hospitalization. The co-primary efficacy endpoints in the study will be the clinical response in the clinically evaluable population and the clinical response in the clinical modified intent-to-treat population at the TOC visit. The primary efficacy analyses will first determine whether tigecycline is noninferior to levofloxacin. If tigecycline is found to be noninferior, the analyses will determine whether tigecycline is statistically better than levofloxacin.